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Abstract Leukemia progression and relapse is fueled by
leukemia stem cells (LSC) that are resistant to current treat-
ments. In the progression of chronic myeloid leukemia
(CML), blast crisis progenitors are capable of adopting more
primitive but deregulated stem cell features with acquired
resistance to targeted therapies. This in turn promotes LSC
behavior characterized by aberrant self-renewal, differentia-
tion, and survival capacity. Multiple reports suggest that cell
cycle alterations, activation of critical signaling pathways,
aberrant microenvironmental cues from the hematopoietic
niche, and aberrant epigenetic events and deregulation of
RNA processing may facilitate the enhanced survival and
malignant transformation of CML progenitors. Here we
review the molecular evolution of CML LSC that promotes
CML progression and relapse. Recent advances in these
areas have identified novel targets that represent important
avenues for future therapeutic approaches aimed at selec-
tively eradicating the LSC population while sparing normal
hematopoietic progenitors in patients suffering from chronic
myeloid malignancies.
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Introduction
Diagnostic and therapeutic strategies that predict and
prevent cancer progression represent compelling unmet
medical needs. While advanced cancers are diverse in
phenotype, they often share essential functional proper-
ties ascribed to stem cells such as the capacity to become
quiescent, acquire multi-lineage differentiation potential,
survive and self-renew [1]. Early insight into the molec-
ular pathogenesis of cancer stemmed from the discovery
of activating oncogenes such as the Philadelphia chro-
mosome positive (Ph
+), and its constitutively active
BCR-ABL protein tyrosine kinase product, in chronic
myeloid leukemia (CML) [2–4]. CML represents an im-
portant paradigm for understanding the molecular evolu-
tion of cancer because it was the first cancer shown to be
initiated at the hematopoietic stem cell level by BCR-
ABL; the first cancer found to undergo blastic transfor-
mation following malignant reprogramming of committed
progenitors [5, 6]; and the first target of molecular ther-
apy (eg, imatinib, dasatinib) based on targeting patholog-
ically activated kinases such as BCR-ABL [7].
While the current CML prevalence of 24,000 affected
patients in the United States (http://www.leukemia-
lymphoma.org) i sr e l a t i v e l yl o w ,i ti se x p e c t e dt oi n c r e a s e
significantly over the next 20 years as a result of widespread
use of BCR-ABL tyrosine kinase inhibitor (TKI) therapy.
Previous reports showing preclinical and clinical data demon-
stratethatdiscontinuationofTKItherapyresultsinresurgence
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DOI 10.1007/s11899-012-0121-6of disease [8￿], suggesting that quiescent BCR-ABL1-
expressing progenitors with enhanced self-renewal and sur-
vival capacity persist and drive disease progression [9]. Un-
fortunately, a growing proportion of patients are intolerant or
non-compliant either because they become inured to the fact
that they have a potentially fatal disease or cannot afford
expensive TKI therapy. Ultimately, a significant percentage
of patients are expected to develop TKI resistance driven by
quiescent leukemia stem cells (LSC). This has provided the
impetus for developing sensitive LSC molecular detection
systems as well as LSC targeted therapeutic elimination strat-
egies. The development of new clinical and therapeutic
approaches aimed at detection and elimination of LSC that
fuel therapeutic resistance and blastic transformation will
represent an important step forward in treating patients with
CML and related disorders.
Malignant progenitors play an integral role in disease pro-
gressionandtherapeuticresistanceinCML,andthemolecular
eventsthatare responsible for the generationand maintenance
of quiescent and therapeutically recalcitrant, or resistant, LSC
have been a topic of intense investigation. Malignant reprog-
ramming of progenitors can occur via abnormal activation of
signal transduction pathways and epigenetic events that regu-
late survival, differentiation, and self-renewal (Fig. 1). Blast
crisis (BC) LSC evolve from an expanded myeloid progenitor
pool that gains the capacity to self-renew, become dormant
and survive in select hematopoietic niches under malignant
conditions—characteristics that underlie their particular resil-
ience to therapeutic treatments. In recent years, much effort
has been expended both preclinically and in clinical trials
toward developing and testing therapeutic approaches aimed
at selectively eradicating the LSC population while sparing
the normal hematopoietic stem cells (HSC) in patients suffer-
ing from chronic myeloid malignancies.
CML BC LSC Drive Disease Progression
and Therapeutic Resistance
Previous studies indicate that BCR-ABL-positive progeni-
tors persist in CML patients despite TKI therapy [10]. This
may be attributable in part to quiescent LSC residing in
protective niches that acquire additional mutations over time
and evade therapeutic treatments. Moreover, bidirectional
signaling between LSC and the bone marrow niche might
promote malignant cues in LSC-supportive hematopoietic
microenvironments characterized by inflammatory signaling
and stimulation of cytokine production and interferon path-
ways that facilitate the reprogramming of progenitors to
evolve into BC LSC. Thus, this unique population of dor-
mant progenitors represents an important cellular basis of
disease relapse derived from a resurgence of therapeutically
recalcitrant LSC, and therapies aimed at eradicating these
cells could represent an important step forward toward curb-
ing therapeutic resistance. The molecular mechanisms gov-
erning the evolution of normal HSC into malignant
progenitors have not been completely elucidated. While
BC LSC are known to evolve from an expanded myeloid
progenitor pool with enhanced survival and self-renewal
abilities and acquired quiescence, these cells are distinct
from the chronic phase (CP) CD34
+CD38
− population that
has been previously considered as CML LSC. Recent data
suggest that deregulation of pathways governing progenitor
quiescence, survival and self-renewal, as well as epigenetic
Fig. 1 Schematic diagram of
molecular mechanisms driving
malignant transformation of
hematopoietic progenitors into
leukemia stem cells in chronic
myeloid leukemia
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persistence and therapeutic resistance.
Evidence suggests that patients with advanced CML de-
velop resistance rapidly and generally do not achieve durable
complete molecular remission with single-agent TKI therapy
as a result of a failure of imatinib to eradicate LSC [10, 11].
This dormant population of cells is relatively resistant to
traditional cytotoxic chemotherapies and molecular therapies
that target rapidly dividing cells in CML, and thus constitutes
an important reservoir of cells that triggers resurgence of
disease. Another issue that needs to be addressed is the pos-
sibility that adding a new molecular inhibitor to existing
treatment with TKI could prove clinically useful. However,
determining the precise molecular targets that would be most
effective to pursue using combination therapeutic strategies
requires a comprehensive understanding of the molecular
mechanisms that drive the induction and maintenance of the
quiescent and therapeutically resistant LSC population.
Quiescent BC LSC Persist and Contribute
to the Progression of CML
Although the precise molecular mechanisms fueling the
generation of treatment-resistant LSC remain elusive, it is
quite possible that one critical factor might be deregulation
of the cell cycle, which may promote quiescence of LSC
that allows this population to evade therapies targeting met-
abolically active cells. The normal progression of cells
through the various stages and checkpoints that guide this
process requires the precise regulation of a complex cho-
reography of molecular events involving cyclins, cyclin-
dependent kinases, and their negative regulators including
p27(kip1) and p21(cip1). Under homeostatic conditions,
the activities of these components are tightly regulated. In
contrast, abnormal tyrosine kinase-directed phosphoryla-
tion of cell cycle regulatory proteins and mis-localization
of cell cycle proteins have been implicated in de-
regulation of the cell cycle in BCR-ABL expressing cells
[12]. Additionally, signal transduction molecules implicat-
ed in cell survival and self-renewal—two critical charac-
teristics of quiescent LSC—have been linked to key
regulators of the cell cycle.
It is unclear why under certain conditions this may pro-
mote uncontrolled proliferation while in other contexts cell
quiescence may be favored. However, it is possible that cues
from the microenvironment might be involved. Several lines
of evidence support the contention that LSC localized to the
bone marrow niche are dormant and resistant to traditional
cytotoxic therapies. Specific signals from the surrounding
stromal cells might promote LSC cell cycle arrest and allow
them to persist even during treatment with TKI therapies.
Altered interactions between CML LSC and the bone
marrow microenvironment can occur as a result of direct
intercellular contact; secreted factors such as cytokines or
chemokines; or through microenvironmental matrix proteins
that regulate cellular adhesion and migration, and growth
factor receptor and integrin signals [13], among other activ-
ities. Recent evidence provides new insight into the poten-
tial contribution of the microenvironment to the initiation
and progression of myeloid disorders and leukemia, and
may provide a unique area for the development of combi-
nation therapeutic strategies aimed at eradicating the resis-
tant LSC population in CML.
Maintenance of LSC in Supportive Hematopoietic
Niches
Previous reports support the hypothesis that LSC fuel ther-
apeutic resistance, relapse, and disease progression from CP
to BC as a result of enhanced survival and self-renewal
combined with a propensity to become dormant in support-
ive microenvironments [14]. To date, therapies aimed at
eradicating quiescent LSC while sparing normal HSC func-
tion have remained elusive [14]. Development of such ther-
apeutic strategies targeting LSC in supportive niches would
represent an important complement to current standard of
care TKI treatments. Recent studies have made strides to-
ward elucidating the role of the hematopoietic microenvi-
ronment in LSC generation and maintenance. Under
physiological conditions, normal HSC residing in the bone
marrow niche benefit from cell-extrinsic support derived
from the heterogeneous cell populations that comprise the
surrounding hematopoietic microenvironment. The cell
types present in this unique environment include primarily
cells of mesenchymal lineages (osteoblasts and other pro-
genitors, osteocytes), endothelial and perivascular cells, and
adipocytes [15]. Together with the HSC that reside in the
bone marrow, these cell populations exhibit bidirectional
signaling that suggests the existence of a functional partner-
ship between HSC and the resident stromal cells. Thus, in
the development and progression of CML, defects in either
LSC or the surrounding microenvironmental cells could
deregulate critical cellular pathways and impair the normal
process of hematopoiesis.
The role of the hematopoietic microenvironment in the
development and progression of leukemic disorders has
been a subject of intense investigation [15, 16￿, 17￿]. Previ-
ous studies suggest that cell-intrinsic defects drive myeloid
progenitor expansion and malignant reprogramming in
CML, while more recent data favor a primary role for a
defective microenvironment in the generation of LSC [16￿].
This presents an opportunity for consideration of the relative
contributions of “nature versus nurture” to leukemic devel-
opment at the microenvironmental level.
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induced oncogenesis can drive the development of myelo-
dysplasia [16￿]. Interestingly, genetic manipulation of spe-
cific subsets of stromal cells can alter differentiation,
proliferation, and apoptosis of heterologous cells. Specifi-
cally, deletion of Dicer1 in mouse osteoblast progenitors
results in disruption of homeostasis and development of a
myelodysplastic phenotype in deficient mice [16￿]. Striking-
ly, transplantation of normal HSC from wild-type mice into
the Dicer1 deleted mice also resulted in the development of
myelodysplasia in the recipient animals. This supports a
critical role for perturbations in the bone marrow microen-
vironment in the development of disorders of myeloid pro-
genitors, however disease initiation and progression to BC
driven by alterations intrinsic to malignant CML progenitors
has also been well characterized.
The truth likely lies somewhere in between the two poles
of niche-induced versus LSC-autonomous oncogenesis,
wherein subtle changes in both HSC and the bone marrow
microenvironmental stromal cells act in concert to drive
generation of LSC and persistence of disease, and further
exacerbate aberrant regulation of cellular pathways. Malig-
nant CML progenitors harboring mutations and epigenetic
alterations that drive enhanced survival and self-renewal
might perpetuate pro-leukemic signals from the microenvi-
ronment via abnormal inter-cellular signaling with stromal
cell populations. Moreover, recent reports indicate that ima-
tinib treatment promotes migration of CML progenitors to
the bone marrow via activation of inflammatory signaling
receptors (eg, CXCR4), which fosters the survival of quies-
cent LSC in the bone marrow niche [18].
Aberrant Regulation of Signal Transduction Drives
Malignant Reprogramming of CML Progenitors
The precise molecular mechanisms driving malignant
reprogramming of progenitors into LSC in BC CML have
remained elusive. Myeloid LSC evolve from granulocyte-
macrophage progenitors (GMP) that aberrantly activate self-
renewal pathways and drive therapeutic resistance [6, 11,
19, 20]. These critical stem cell signaling pathways repre-
sent important alternative targets for development of molec-
ular therapies that might subdue the resistant LSC
population and prove to be useful in the clinic in combina-
tion with current TKI treatments. Previous studies estab-
lished the concept of malignant progenitor reprogramming
through subversion of stem cell pathways, such as Wnt/β-
catenin [20], which has been shown to play a critical role in
the survival of LSC [21] with acquired imatinib resistance
[22]. Other components of Wnt signaling pathways have
also been implicated in the pathogenesis of CML. While
sequencing of human LSC revealed very few alterations at
the DNA level, there were three SNPs that predicted splic-
ing of the negative Wnt pathway regulator—glycogen syn-
thase kinase 3β (GSK3β). Targeted RNA sequencing
revealed a recurrent misspliced, non-functional isoform of
GSK3β that predominated in the GMP population, leading
to β-catenin activation and enhanced self-renewal [19].
Recent advances have been made toward targeting these
signaling molecules with the aim of eradicating LSC or
sensitizing them to TKI therapies. Candidate therapies under
development include inhibitors of Wnt/β-catenin signaling.
New evidence suggests that such therapeutic approaches
may hold promise for targeting imatinib-resistant LSC pop-
ulations, and may represent an important therapeutic strate-
gy in CML and other leukemic disorders. However, current
reports of therapeutic Wnt inhibition in models of CML are
limited and will require further in vivo studies to elucidate
the therapeutic efficacy of these approaches.
Deregulation of Cell Survival Pathways in CML LSC
and Therapeutic Strategies
Another potential therapeutic target that has received recent
attention is cell survival gene pathways that are aberrantly
activated in CML LSC. For example, deregulation of the
anti-apoptotic B-cell lymphoma/leukemia-2 (BCL2) family
of genes contributes to LSC apoptosis resistance in the bone
marrow microenvironment. Overexpression of BCL2 family
genes has been observed in human BC CML and may fuel
LSC survival (Goff et al., unpublished results). Human stem
cells express myriad pro-death and pro-survival BCL2 fam-
ily members, each with alternative splice isoforms, render-
ing the study of human stem cells essential for predicting
both the potential efficacy and toxicity of targeted BCL2
inhibition as a therapeutic strategy to eliminate apoptosis
resistant LSC. Recent data demonstrate that human LSC
express numerous anti-apoptotic BCL2 family splice iso-
forms. This family of proteins provides a promising can-
didate for LSC-targeted strategies aimed at selectively
eliminating dormant CML LSC. Since multiple BCL2
family members appear to be involved, it is possible that
a pan-BCL2 inhibitor will be required to abrogate LSC
survival.
We have recently demonstrated that potent inhibitors of
BCL2 pro-survival family proteins significantly inhibit LSC
survival, at doses that spare normal hematopoietic progeni-
tors in BC CML (Goff et al., unpublished results). Thus,
anti-apoptotic BCL2 gene overexpression plays a key role in
therapeutic resistance of quiescent BC CML LSC. Combi-
nation therapies targeting activated kinases in concert with
anti-apoptotic factors such as the BCL2 family may repre-
sent a key strategy toward preventing therapeutic resistance
and may be more broadly applicable to LSC in other
malignancies.
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LSC and Therapeutic Strategies
Alternative important potential targets for therapeutic devel-
opment in CML are pathways that regulate stem cell self-
renewal. For example, one critical stem cell-associated self-
renewal gene that has been implicated in the pathogenesis of
myeloid and other malignancies is Shh [23]. Shh activation,
through mutations and/or abnormal transcriptional regula-
tion and over-expression of downstream effector molecules
such as the GLI family (GLI1, GLI2, GLI3) has been linked
to the development of varied tumor types, from those affect-
ing brain, skin, and muscle to cancers in other organs
including the pancreas, prostate, lungs, and gastrointestinal
tract [24]. Shh signaling plays a role in embryonic pattern-
ing and fetal development [25], as well as serving critical
functions in adult cell populations such as cell cycle regu-
lation in the hematopoietic system [26].
While in hematological malignancies, previous studies
have linked Shh activation to cancer stem cell (CSC) genera-
tion and disease progression [27], others have shown that Shh
signaling modulates the hematopoietic niche during disease
progression [28]. In recent studies we demonstrated that treat-
ment of human BC LSC engrafted immunodeficient mice
with a selective Shh inhibitor reduced leukemic burden in a
niche-dependent manner commensurate with GLI downregu-
lation(Shihetal.,unpublished results).Interestingly,Shhhas
also been implicated in cell cycle regulatory activities such
as cell growth (via cyclin D) and proliferation (via both
cyclin D and cyclin E) [29], which may be responsible in
part for the malignant potential of abnormal activation of this
pathway in adult tissues. While precise regulation of hedge-
hog signaling pathways plays an indispensable role in nor-
mal embryonic development, it is becoming clear that
malignant reprogramming driven by abnormal activation of
such survival and self-renewal pathways in mature tissues
may have severe consequences. It is also essential to keep in
mind that none of these individual signal transduction path-
ways acts in a closed system, and as such, active regulation
and cross-talk with other signaling pathways play a dynamic
role in the regulation of discrete signaling events. Intriguing-
ly, previous reports have suggested that crosstalk between
Shh, Wnt, and pathways involving cell cycle regulators
might form an important hub in CML progression [30].
Activation of Malignant Transcriptional Programs
is a Feature of Myeloid Disorders
While thus far we have covered several examples of critical
pathways that may drive LSC generation and maintenance,
including cell cycle, survival, and self-renewal gene fami-
lies, the reality is that a plethora of abnormally regulated
pathways have been implicated in the pathogenesis of CML.
This hints at the possibility that broader reprogramming
events at the DNA and/or RNA level may be responsible
for the downstream molecular events that drive disease
progression. Although abnormal activation of signal trans-
duction pathways promoting cell cycle de-regulation and
malignant cues derived from LSC-supportive hematopoietic
microenvironments may be responsible in part for the de-
velopment and progression of CML, other post-
transcriptional mechanisms may also contribute. Monumen-
tal efforts to date have resulted in the identification of DNA
mutations and translocations (eg, BCR-ABL) that constitute
the initiating oncogenic events in the development of chron-
ic leukemic disorders, however the persistence of LSC and
the rise of therapeutic resistance among patients receiving
long-term TKI therapies indicates that other mechanisms
may fuel leukemic progression and relapse. This has pro-
vided the impetus for elucidating the role of genetic and
epigenetic alterations fueling cancer progression.
LSC dormancy, survival, and self-renewal, properties that
drive both leukemic transformation and therapeutic resis-
tance, occur as a consequence of cell type-specific and
microenvironment-specific alterations in both DNA repair
and RNA processing. Important clues to the molecular path-
ways involved in leukemia initiation and progression have
been revealed previously by mutational analyses of tumors
that described accumulated DNA mutations. In particular,
alterations in TET2—a regulator of cytosine methylation—
have been detected frequently in myelodysplastic syn-
dromes (MDS) and more recently have been reported to
occur as secondary cytogenetic abnormalities in acute and
blast phase CML [31]. While a plethora of studies investi-
gating molecular events that fuel human CML progression
have focused on acquired DNA mutations, recent data show
that aberrant processing of coding and non-coding RNAs
represent an important source of proteomic diversity driving
therapeutic recalcitrance and relapse [32￿]. Recently, novel
mutations in components of the RNA splicing apparatus
have been described in MDS [33, 34￿, 35], and it is possible
that abnormalities in the spliceosome may also contribute to
aberrant myeloid development in CML. Together these
observations suggest that post-transcriptional modifications
are pivotal events in leukemogenesis. Thus, these cellular
processes represent a source of malignant epigenetic adap-
tation that may be responsible for broad functional changes
in the LSC transcriptome and proteome, and are worthy of
further investigation.
Abnormal RNA Processing Events in CML Progression
As discussed above, previous studies have implicated the
generation of novel splice acceptor sites in critical signaling
molecules, such as GSK3β, can result in the generation of
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ming of progenitors into LSC that drive blastic transforma-
tion of CML [19, 36]. However, the mechanisms governing
aberrant splicing have not been elucidated, and may provide
another group of alternative molecular targets for therapeu-
tic development in CML. Notably, alternative splicing of
other CSC markers, such as CD44, has been associated with
invasive breast cancer while CD47 splice isoforms are over-
expressed by CSC in a number of tumors and prevent
macrophage-mediated phagocytosis [37].
Alternative splicing also plays a central role in the main-
tenance of fetal and adult HSC and may have important
functions in LSC and disease progression. Cancer-
associated alterations in splicing have been shown to affect
genes controlling apoptosis (BCL2, GSK3β, Bcl-x, p53, and
caspase-2) and drug resistance [38]. One example is the
switch in BCL2 family member isoform expression from
the pro-apoptotic to pro-survival isoforms that contributes to
apoptosis resistance of the LSC and has been described and
both observed in both MDS and CML disease progression.
As discussed in more detail above, recent RNA sequencing
and qRT-PCR data demonstrate that a number of anti-
apoptotic BCL2 splice isoforms are highly expressed by
human CML LSC (Goff et al., unpublished results). The
BCL2 family represents an important therapeutic target and
determination of the BCL2 family member isoform expres-
sion may be a valuable diagnostic tool for patients with
CML and other myeloproliferative neoplasms in the
clinic.
Moreover, in CML novel splicing events have been
identified in transcripts of other genes involved in the
regulation of hematopoietic development and cell fate
determination (Ikaros) [39], in cell growth and senescence
factors (Gfi1b, hTERT) [40, 41], and even in BCR-ABL
itself, an event which may contribute to imatinib resis-
tance [42]. Although somatic cis-acting mutations that
affect splicing may contribute to alternative transcript
generation in cancer, aberrant expression of splicing fac-
tors is one possible source of human neoplasia-associated
transcriptome diversity. Notably, recent landmark studies
have identified mutations in components of the cellular
splicing machinery that are associated with the develop-
ment of human MDS [33, 34￿, 35]. However, it remains
to be elucidated whether similar mechanisms might con-
tribute to abnormal splicing activities in CML.
Previous reports have proposed that general changes in
pre-mRNA splicing as a result of p210BCR/ABL kinase
activity may contribute to CML pathogenesis [43]; however
the mechanisms promoting abnormal RNA processing in
CML remain to be elucidated. Recent studies reveal that
genes with predicted RNA editing events are significantly
enriched in cancer-related pathways in breast cancer and
glioblastoma, supporting a role for abnormal RNA
processing in gene product diversity in cancer pathogenesis
[44]. Although increased expression of RNA editing
enzymes has been implicated in the mutational evolution
of other cancers [45], little is known about the role of RNA
editing in human LSC survival, cell fate determination, and
self-renewal. Taken together, aberrant RNA processing
and splicing may act as critical regulators of LSC gen-
eration and maintenance, and perhaps more importantly,
it sets the stage for CSC elimination in other human
malignancies.
Conclusions
In the pathogenesis of CML, therapeutically recalcitrant
LSC are thought to fuel disease progression and relapse.
While targeted TKI therapies (BCR-ABL antagonists) have
resulted in improved survival of patients with CP CML, the
prevalence of CML doubled in the U.S. between 2001 and
2009 (http://seer.cancer.gov/). Unfortunately, a growing pro-
portion of patients are non-compliant because they become
inured to the fact that they have leukemia or simply cannot
afford full dose TKI therapy as a result of spiraling annual
costs and thus, progress to advanced phase disease with a 5-
year survival rate of less than 30 %. Thus, elimination of
LSC contributing to therapeutic resistance, the primary
cause of cancer death, is of high clinical importance, and
understanding the molecul a rm e c h a n i s m so fC M LL S C
biology that drive the generation of LSC and their persis-
tence is crucial.
Characteristic features of CML LSC, such as their en-
hanced capacity for survival, self-renewal, and persistence
over time through dormancy, underlie their unique resilience
to conventional therapies. Cell cycle alterations, abnormal
activation of signaling pathways involved in cell survival
and self-renewal, and microenvironmental cues from the ma-
lignant bone marrow microenvironment can facilitate the en-
hanced survival and malignant transformation of CML LSC.
More recently, epigeneticalterations at the RNA level,includ-
ing aberrant splicing and RNA processing, have been impli-
cated in the pathogenesis of CML and MDS. Therapeutic
strategies targeting regulators of cell survival and self-
renewal, or RNA processing pathways, could represent
vital novel components of a potentially curative strategy
for advanced CML that may obviate the need for costly
continuous TKI therapy by increasing sensitivity to
therapy. Such therapeutic strategies could provide a
valuable companion diagnostic with relevance to a
broad group of patients suffering from leukemia and
lymphoma disorders.
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